Sponsor: Merck
Sponsor Study ID: MK3475-A18 / ENGOT-CX11
Study Title: A Randomized, Phase 3, Double Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High risk, Locally Advanced Cervical Cancer (KEYNOTE A18 / ENGOT cx11)
CTO #: 103241
NCT Number: NCT04221945
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Cervix Uteri
Study Objectives: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.